The Danger of Smoking and E-cigarettes in Brazil

Sep.02.2022
The Danger of Smoking and E-cigarettes in Brazil
Smoking is the primary cause of lung cancer in Brazil's Mato Grosso state, with e-cigarettes becoming a popular and dangerous alternative.

In the state of Mato Grosso do Sul in Brazil, there are 15.6 cases of tracheal, bronchial, and lung cancer per 100,000 males and 7.9 cases per 100,000 females, with similar ratios. According to data from the US National Cancer Institute (INCA), these types of tumors are primarily caused by smoking.


Smoking is the second leading cause of cancer in men, with only prostate cancer having a higher incidence rate. In women, it is the third leading cause, following breast and cervical cancer.


Giovanna Figaredo, a pulmonologist who works at the St. Matthew's Hospital in Cubatão, believes that in addition to traditional smoking methods such as cigarettes, cigars, and pipes, electronic cigarettes are becoming a popular and harmful trend, especially among young people.


Many individuals believe that electronic cigarettes are "healthier," but this is a myth. We must uncover the mysterious veil of this information in order to guide people away from consumption. Electronic cigarettes are banned in Brazil because they are unsafe. Many people are even unaware of what they are inhaling, the doctor explained.


This pulmonologist has warned that smoking increases the risk of more than 20 types of cancers, in addition to the most common ones such as lung cancer, bronchial cancer, and tracheal cancer. Furthermore, smoking also increases the risk of cardiovascular diseases such as heart disease and stroke. It can lead to pulmonary diseases like chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, and decreased fertility.


In regards to e-cigarettes, the long-term damage of their use is still largely unknown due to the higher consumption rates of this generation. However, there have been cases of patients with deteriorating lung conditions such as asthma. Additionally, there is EVALI (electronic cigarette or vaping product use-associated lung injury), which is an acute lung disease associated with the use of e-cigarettes," he pointed out.


Nicotine is a disease.


Doctor Giovanna Figueiredo explained that nicotine addiction is considered a disease and is classified under the International Classification of Diseases (ICD). It can lead to physical and psychological dependency.


Experts emphasize that the first step to overcoming the difficulties of quitting smoking is willpower and determination. "I usually guide people to make changes in their daily habits, such as changing the place where they usually keep their cigarettes, delaying the first cigarette of the day as much as possible, and avoiding drinks that encourage smoking, such as coffee and alcoholic beverages. After making these changes, it is important to set a date to permanently quit tobacco use.


Doctors emphasize that certain medications can assist with quitting smoking and also help control withdrawal symptoms and anxiety. They point out that seeking professional help for guidance, planning, and medication prescriptions is crucial when needed.


Statement:


This article is compiled from third-party information and is only intended for industry-related exchange and learning.


This article does not reflect the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The article's translation is only intended for industry-related communication and research purposes.


Due to limitations in the translator's ability, translated articles may not accurately reflect the original text. It is recommended to refer to the original text for accuracy.


In regards to any domestic, Hong Kong, Macao, Taiwan, or foreign affairs, 2FIRSTS maintains complete alignment with the Chinese government.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia's new retail tobacco permit system took effect October 1, requiring sellers of vapes, nicotine products and related devices and accessories to obtain a Retail Tobacco Permit for each business location. Virginia ABC said more than 3,000 businesses applied in September alone, creating a processing backlog. Qualifying applicants that filed before October 1 may temporarily operate under a Letter of Authorization. The new store-level permit also sits alongside Virginia's existing vape product directory, where sales of unlisted liquid nicotine or nicotine vapor products can trigger civil penalties starting at $5,000.
Regulations
Oct.03
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
SnowPlus has introduced a nicotine-free version of DASH in South Korea, adapting an existing overseas disposable platform for the local market. The Korean version retains the series’ flat duckbill-style mouthpiece, ceramic heating architecture and disposable form factor while reducing nicotine content to 0%. By comparison, the overseas DASH 4000 platform typically features 7.5ml of prefilled e-liquid, up to 4,000 puffs and a 530mAh rechargeable battery, with nicotine-containing variants available in some markets. The product update centers on formulation localisation rather than a new hardware generation.
Aug.31
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22